Phase 1 trial of trametinib and gilteritinib for the treatment of relapsed or refractory acute leukemia patients

What you commit to

• Study type: Interventional · Phase 1
• Planned participants: 54
• 6 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with acute leukemia (ALL or AML) that came back or did not respond to treatment, who have no other treatment options.

Age

18 years or older

Sex

All sexes can join.

Disease stage

Acute lymphoblastic (ALL) or acute myeloid (AML) leukemia that has relapsed or did not respond to treatment, in people who cannot have treatment meant to remove all of the disease.

Earlier treatment

People must have no other treatment options available.

Main reasons for not taking part

• Healthy volunteers cannot join.

Read by machine on 9 Nov 2026.

Sites (6)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details